Open Access Highly Accessed Research article

A/C magnetic hyperthermia of melanoma mediated by iron(0)/iron oxide core/shell magnetic nanoparticles: a mouse study

Sivasai Balivada1, Raja Shekar Rachakatla1, Hongwang Wang3, Thilani N Samarakoon3, Raj Kumar Dani3, Marla Pyle1, Franklin O Kroh2, Brandon Walker2, Xiaoxuan Leaym2, Olga B Koper2, Masaaki Tamura1, Viktor Chikan3, Stefan H Bossmann3 and Deryl L Troyer1*

Author Affiliations

1 Department of Anatomy and Physiology, 228 Coles Hall, Kansas State University, Manhattan, KS 66506, USA

2 NanoScale Corporation, 1310 Research Park Drive, Manhattan, KS 66502, USA

3 Department of Chemistry, 213 CBC Building, Kansas State University Manhattan, KS 66506, USA

For all author emails, please log on.

BMC Cancer 2010, 10:119  doi:10.1186/1471-2407-10-119

Published: 30 March 2010



There is renewed interest in magnetic hyperthermia as a treatment modality for cancer, especially when it is combined with other more traditional therapeutic approaches, such as the co-delivery of anticancer drugs or photodynamic therapy.


The influence of bimagnetic nanoparticles (MNPs) combined with short external alternating magnetic field (AMF) exposure on the growth of subcutaneous mouse melanomas (B16-F10) was evaluated. Bimagnetic Fe/Fe3O4 core/shell nanoparticles were designed for cancer targeting after intratumoral or intravenous administration. Their inorganic center was protected against rapid biocorrosion by organic dopamine-oligoethylene glycol ligands. TCPP (4-tetracarboxyphenyl porphyrin) units were attached to the dopamine-oligoethylene glycol ligands.


The magnetic hyperthermia results obtained after intratumoral injection indicated that micromolar concentrations of iron given within the modified core-shell Fe/Fe3O4 nanoparticles caused a significant anti-tumor effect on murine B16-F10 melanoma with three short 10-minute AMF exposures. We also observed a decrease in tumor size after intravenous administration of the MNPs followed by three consecutive days of AMF exposure 24 hrs after the MNPs injection.


These results indicate that intratumoral administration of surface modified MNPs can attenuate mouse melanoma after AMF exposure. Moreover, we have found that after intravenous administration of micromolar concentrations, these MNPs are capable of causing an anti-tumor effect in a mouse melanoma model after only a short AMF exposure time. This is a clear improvement to state of the art.